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Generally, there are large number of people suffer from cogni-
tive impairment, including impairment of learning, memory and
attention.1 However, the exact mechanisms for cognitive dysfunc-
tion have remained unclear, oxidative stress and neuroinflamma-
tion may be in part, responsible for memory and learning
impairment.2 In particular, the elderly people are most susceptible
to cognitive impairment that may result from infection,3 in addi-
tion, the process of aging itself is associated with neuroinflamma-
tion involving production of proinflammtory cytokines and
microglial activation.4 Also, neuroinflammation occurs in other
conditions that may lead to pathological changes in the brain as
postoperative dysfunction, ischemic stroke, Alzheimer disease
(AD), multiple sclerosis or Parkinson disease.5 In some animal
models, exposure to bacterial endotoxins, or viral coat proteins,
will stimulate immune system resulting in memory and learning
deficits.6
Lipopolysaccharide (LPS) is a component obtained from the
outer cell membrane of gram-negative bacteria.7 It is a potent
endotoxin that inducing inflammation in experimental studies,
and it highly resist the degeneration by enzymes and hence it pro-
vides an inflammatory stimulus that can persist for long time.8 It
can promote the production of proinflammatory cytokines with
subsequent production of free radicals and oxidative stress.9
Lactoferrin (LF) is a non-heme iron-binding glycoprotein of
transferrin family.10 It is present in milk, tears, saliva, and other
external secretions, and in the secondary granules of neutrophils.11
Normally, low concentrations of LF are present in the blood.12 LF is
a multifunctional protein that is involved in a large number of
physiological functions including anti-inflammatory, anti-stress,
anti-nociception, antioxidant, cell proliferative, and immunoregu-
latory properties,13 regulation of iron absorption,10 anticarcino-
genic, and antimicrobial activity.14 In addition, LF is produced in
the brain, its levels in aging and neurodegenerative disorders are
found to be increased in central nervous system, suggesting that
it may have endogenous role in neuroprotection.15 Dietary LFrelatively resist degradation in gastrointestinal tract (GIT) and is
actively transported into the brain.16
However, to our knowledge, there were no published studies to
date the effect of LF on memory impairment in adult rats. So, in the
present study, we examined possible protective effect of LF on
LPS-induced memory impairment in albino rats. Also, possible
mechanisms would be discussed.
2. Materials and methods
2.1. Animals
Thirty male albino rats of local strain, aged 12–16 weeks old,
weighing 200–240 g. They were obtained from the animal house
of Tanta University of Medical Sciences. The animals were housed
in clean cages, five rats per each cage, and had free access to food
and water. They are maintained at suitable temperature (22 ± 2 C
room temperature) under controlled 12–12 h light dark cycle. This
study was conducted in accordance with the guidelines for the ani-
mal experimental protocols of Tanta Faculty of Medicine.
2.2. Drugs and chemicals
LPS was dissolved in saline and injected in rats. It was
purchased from Sigma-Aldrich chemical Company (Co.), LF was
purchased from Meivo International Pharmaceutical Industries
Co., in the form of sachet freshly prepared in distilled water.
2.3. Experimental protocols
Animals were divided into three groups (n = 10 per group).
(1) The normal control group: the animals received saline (1ml/
kg/day) intraperitoneal (i.p.), as a vehicle, for 12 weeks.
(2) LPS-group: the animals received saline (1ml/kg/day)
intraperitoneal (i.p.) for 11 weeks. From the start of the
12th week, the animals received LPS (1mg/kg/day i.p.)17 for
one week, and 2 h prior to passive avoidance (PA) test.
(3) LF-treated group: the animals received LF (500 mg/kg/day)18
orally via intragastric tube for 12 weeks. From the start of
the first week, the animals received LPS (1mg/kg/day i.p.)
Table 1
Effect of LF on first day latency and retention latency of PA test in albino rats.
Parameters Control group LPS-group LF-group
First day latency (sec) 42.2 ± 4.61 45.0 ± 3.80 46.5 ± 3.69
Retention latency (sec) 261.0 ± 27.57 46.10 ± 4.43a 244.4 ± 25.43b
Data are given as mean ± SD.
a P < 0.05 vs control group.
b P < 0.05 vs LPS-group.
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30 min after LF.
2.4. Passive avoidance (PA) test
At the end of the 12th week of experiment, PA test was done as
following:
Light-dark apparatus was used to evaluate the emotional mem-
ory depending on fear-conditioning learning. The animals of all
studied groups learned to avoid a place that associated with repul-
sive stimulus. The learning index in this experiment would be the
reduction of latency. The PA apparatus consisted of two compart-
ments. One was illuminated and the other was dark. The two com-
partments were separated by a door.
A training trial was done.19 A pre-training trial was done on the
first day of training, in that trial, rats were placed individually into
the light compartment. The door between the two compartments
was opened after 30 sec and the animal was able to move freely
into the dark compartment.
60 min after the pre-training trial, a training trial was done. Rats
were again placed in the light compartment. After 30 s, the door
between the two compartments was opened. When the animal
entered the dark compartment completely, the door was closed
and 3–5 electric shock (0.5 mA) was applied to the floor of the
compartment. The time taken to enter the dark compartment
was estimated as the training latency. If the animal failed to enter
the dark compartment within 300 sec, it was excluded from the
experiment. After the training trial, the animals were removed
from the dark compartment and returned back to their cages.
24-h after the training trial, a retention trial was done. Evalua-
tion of recall of this inhibitory stimulus was done by placing the
animals in the light compartment and recording their latency to
enter the dark compartment. No electric shock was applied in this
trial. If the animal did not enter the dark compartment within 300
sec, it was returned to its cage, and a latency of 300 sec was
recorded. So, the latency is a measure for retention performance
of the PA response.2.5. Biochemical measurements
At the end of experiments, the animals were sacrificed by cervi-
cal decapitation. The brains were collected, they were homoge-
nized followed by centrifugation. The supernatants were stored
at 80 C until measurement of the following: malondialdehyde
(MDA) was measured spectrophotometerically according to the
method of Csallany et al.,20 which resulting in formation of a red
compound. The maximum absorbance of this compound was mea-
sured at 532 nm, reduced glutathione (GSH) was measured spec-
trophotometerically according to the method described by Hissin
and Hilf21 according to the instructions of the assay kit. Also, tumor
necrosis factor-alpha (TNF-a), interleukin-1b (IL-1b), nuclear factor
kabba-B (NF-kB) and brain derived neurotrophic factor (BDNF)
were determined by were determined using commercial ELISA kits
according to the instructions of the manufacturer. Finally, acetyl-
cholinestrase activity was estimated colorimetrically according to
the method of Ellman et al.22 and expressed as percentage of con-
trol. The protein content in the supernatant was measured accord-
ing to the method of Bradford.23Fig. 1. Effect of LF on brain levels of MDA and GSH in albino rats. Data are given as
mean ± SD. aP < 0.05 vs control group, bP < 0.05 vs LPS-group.3. Statistical analysis
The data were shown as the mean ± standard deviation. Data
from the study were analyzed using one–way ANOVA. All the anal-
yses were performed using SPSS for windows (Version 21.0).4. Results
4.1. Effect of LF on first day latency and retention latency of PA test in
albino rats
As shown in Table 1, as regard the first day latency, there was
no significant differences between all studied groups (P > 0.05).
However, retention latency significantly reduced in LPS-group as
compared to the normal control group. LF treatment for 12 weeks
significantly increased retention latency as compared to the LPS-
group. It was observed the retention latency returned back to the
normal control value by LF treatment.
4.2. Effect of LF on brain levels of MDA and GSH
Compared to the control rats, LPS injection significantly
increased MDA level in the brain. Administration of LF, signifi-
cantly decreased MDA level as compared to the LPS-group. The
levels of MDA returned back to the control values after LF treat-
ment Fig. 1(A).
As regard GSH, there was significant decrease in GSH level in
LPS-group as compared to the normal control group. While, LF
treatment significantly increased GSH levels as compared to LPS-
group. Its levels returned back to the normal control values by LF
treatment Fig. 1(B).
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rats
These were presented in Table 2, the levels of TNF-a, IL-1b, and
NF-jB significantly increased with LPS injection as compared to
the normal control rats. While, LF treatment, showed significant
reduction in TNF-a, IL-1b, and NF-jB levels compared to the LPS-
group. But, their levels were still significantly higher if compared
to the normal control group.
4.4. Effect of LF on brain levels of BDNF and acetylcholinestrase activity
in albino rats
Fig. 2(A) showed that BDNF significantly decreased after LPS
injection as compared to the control group. LF administration sig-
nificantly increased BDNF levels compared to the LPS-group. It was
observed that after LF treatment, BDNF returned back to the con-
trol values.
As shown in Fig. 2(B), LPS injection significantly increased levels
of acetylcholinestrase activity compared to the control group. The
rats treated with LF showed insignificant change in the levels of
acetylcholinestrase activity compared to the LPS-group, but these
levels significantly increased if compared to the normal control
group.Fig. 2. Effect of LF on brain levels of BDNF and acetylcholinestrase activity in albino
rats. Data are given as mean ± SD. aP < 0.05 vs control group, bP < 0.05 vs LPS-group.
Table 2
Effect of LF on brain levels of TNF-a, IL-1b, and NF-jB, in albino rats.
Parameters Control group LF-group LF-group
TNF- (pg/mg protein) 131.20 ± 10.78 471.20 ± 15.63a 269.10 ± 15.24a,b
IL-1 (pg/mg protein) 41.10 ± 6.42 255.0 ± 30.33a 157.80 ± 15.78a,b
NF-jB (ng/mg protein) 79.70 ± 7.93 375.70 ± 17.12a 295.50 ± 11.38a,b
Data are given as mean ± SD.
a P < 0.05 vs control group.
b P < 0.05 vs LPS-group.5. Discussion
In the present study, LF improved memory impairment induced
by i.p. administration of LPS in the adult rats. The neuroprotective
effect of LF on memory impairment may be related to its antioxi-
dant, anti-inflammatory effects, inhibiting the increase of NF-jB
with subsequent inhibition of apoptotic pathway as well as
increasing BDNF, but it had no effect on acetylcholinestrase activity
in the brain.
The present study was the first one that was done to test the
neuroprotective effect of LF on adult brain in rats. All previous
studies were used to demonstrate the effect of LF on brains of
immature or newly born rats.
PA test was used to detect the memory impairment caused by
LPS injection. The results of the present study showed that no sig-
nificant differences between all the studied groups during the first
day latency, but there was a significant decrease in the time of
latency to enter the dark compartment in LPS group as compared
to the normal control group. These results were confirmed with
previous researches reporting that LPS injection induced memory
retention impairment of PA.6
The results of our study showed that administration of LF for
12 weeks, improved the memory impairment in rats as proved
by increasing the retention latency of PA as compared to LPS group.
In accordance to these results, it was reported that the bovine LF
administration during postnatal development of rats, improved
PA test.18
The exact mechanism by which LF improved LPS-induced
memory impairment in rats could not be elucidated. But, it could
be explained by its direct action on the brain via antioxidant,
anti-inflammatory effects, and increasing BDNF as evidenced in
the results of the present study. Another possible mechanism could
explain the improvement of the memory impairment might be due
to transferrin-mediated iron transport of LF in the brain, it could
be evidenced by that iron deficiency during early life led to the
subsequent impairment of both PA and active avoidance learning
in rats.24 Also, it was suggested that LF treatment promoted the
growth of beneficial bacteria called bifidobacteria in the gut of
the treated animals, it was observed that bifidobacteria might
exert antidepressant or anxiolytic effects in both human and
animal models.25
The brain is highly susceptible to oxidative damage that has
induced by reactive oxygen species (ROS), as it produces large
amounts of ROS due to its very high blood perfusion, high aerobic
metabolism and its poor antioxidant defense mechanism.26 There-
fore, oxidative stress of the brain plays an important role in cogni-
tive impairment and neuronal injury.27 Previous studies have
demonstrated that i.p. injection of LPS caused significant changes
in oxidative stress markers in the brain of mice.28
In the results of the present work, there was significant increase
of MDA levels with concomitant significant decrease of GSH levels
in the brain in LPS group as compared to the normal control group.
Also, our results showed that the abnormal changes in MDA and
GSH levels were prevented by LF treatment, suggesting that the
neuroprotective of LF might be explained by its antioxidant effects.
These results were in accordance with previous researches demon-
strating that LF has ROS-scavenging properties.29
Previous studies have reported that LPS caused activation of
microglia with subsequent induction of pro-inflammatory cytoki-
nes as TNF-a and IL-1b via activation of NF-jB pathway in the
mouse brain.30 In fact, activation of NF-jB leads to pathological
inflammatory processes in the glial cells, hence, the transcription
factor NF-jB could be blocked or reduced by anti-inflammatory
compounds.31
In the present study, i.p. injection of LPS significantly increase
TNF-a and IL-1b levels in rat brain. While, LF treatment for
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inflammatory cytokines including TNF-a and IL-1b with concomi-
tant reduction of NF-jB in the brain with subsequent blunting of
neuronal apoptosis. Thus, LF had the ability to block the activation
of NF-jB, suggesting that the neuroprotective effect of LF could be
explained by its anti-neuroinflammatory and anti-apoptotic
effects.
BDNF is one of a family of neurotrophic growth factors that
widely expressed in the brain tissue.32 The reduced levels of BDNF
has been implicated in pathophysiology of various CNS diseases,
BDNF regulates neuronal transmission, neuronal plasticity as well
as memory and learning.33
The results of the present study demonstrated that i.p. injection
of LPS significantly reduced BDNF, that was reversed by LF treat-
ment. It is proved that activation of BDNF leads to phosphorylation
and nuclear translocation of cyclic adenosine monophosphate
responsive element binding protein, with subsequent gene tran-
scription that plays an important role in enhancing memory and
learning processes.34 Thus, we could postulate that the increase
in BDNF by LF treatment may be one of the underlying mecha-
nisms to explain how LF improved memory impairment in rats.
Finally, the present study showed that LPS injection signifi-
cantly increased the acetylcholinestrase activity in the brain tissue
that could not be improved by LF treatment, suggesting that LF did
not affect acetylcholinestase activity.6. Conclusion
As proved in the present work, LF could alleviate memory
impairment induced by LPS. Its neuroprotective mechanism might
be explained by antioxidant, anti-neuroinflammatory effects, its
ability to inhibit NF-jB with subsequent anti-apoptotic effect, as
well as increasing BDNF levels. So further studies should be done
to investigate the neuroprotective effect of LF and other possible
mechanisms for its action in human brain, and take in considera-
tion for LF treatment that can be used for prophylaxis as well as
treatment of neurodegenerative diseases resulting from inflamma-
tory or oxidative damage.Conflict of interest
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